Skip to main content

Patient Recruitment Home

Current Protocols

Ethics in Clinical Research

Privacy Notice

FAQ About Clinical Studies

Contact Us

Call the Office of Patient Recruitment at 800-411-1222 to speak with one of our Information Specialists.

For those who are deaf, hard-of-hearing, or speech impaired, the Federal Relay Service provides free telecommunications relay services (TRS).

Se habla español.

Patient Recruitment

Do You Know Someone With Diamond-Blackfan Anemia (DBA)?

a doctor holding a pill capsule

close-up of cells

Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are conducting an investigational treatment study with eltrombopag to help patients with Diamond-Blackfan anemia (DBA). Eligible volunteers must be diagnosed with DBA, especially DBA that has not responded to or recurred despite standard therapies. DBA is an inherited disease that can lead to anemia and ultimately bone marrow failure, with increased risks of cancer. Eltrombopag is a drug that can help patients with aplastic anemia, an acquired bone marrow failure syndrome. Whether it can also help patients with different, inherited bone marrow failures is a point of ongoing research at the NIH. This study will attempt to determine whether eltrombopag is safe and effective for patients with DBA.

Though considered primarily a blood disease, DBA may affect all systems of the body, especially as the treatments involved (chronic transfusions and/or steroids) have wide-ranging effects. Eltrombopag has been shown to help reduce the iron that can build up in DBA patients, and consequently may help reduce some of these side effects. In addition to investigating whether eltrombopag can improve blood cell counts in DBA patients, this study will help answer this question. Travel, food and lodging may be provided consistent with guidelines of the National Heart, Lung and Blood Institute policies.

Study Design:

  • 1-2 visits to the NIH Clinical Center in Bethesda, Maryland before starting drug and then every 6 months while on drug
  • Patients will take eltrombopag over a 6-month period
  • Patients who exhibit improvements after 6 months of taking eltrombopag may be eligible to continue taking eltrombopag for up to 3 additional years

Who Can Particpate:

  • Patients 2 years or older diagnosed with Diamond-Blackfan anemia (DBA)
  • Patients diagnosed with DBA who have not responded to therapy, have relapsed, and/or are unable to tolerate current therapy
  • Patients willing to take eltrombopag for a minimum of 6 months
  • Patients willing to have their blood drawn every two weeks by your home physician

The NIH Clinical Center is America's Research Hospital and is located in Bethesda, Maryland, on the Metro Red line (Medical Center stop).

For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
800-877-8339 TTY / ASCII
Se habla español
Email: PRPL@cc.nih.gov

Or go online:
https://go.usa.gov/xdNyc
Refer to study # 20-H-0021

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung and Blood Institute (NHLBI)

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 03/02/2020

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at http://www.cc.nih.gov/disclaimers.html